Plan Group Financial LLC Makes New $273,000 Investment in Eli Lilly and Company (NYSE:LLY)

Key Points

• Plan Group Financial LLC acquired a new stake in Eli Lilly and Company, purchasing 331 shares valued at approximately $273,000 during the 1st quarter.
• Institutional investors currently hold 82.53% of Eli Lilly's stock, reflecting significant interest from large financial entities.
• Analysts have mixed ratings on Eli Lilly, with an average rating of "Moderate Buy" and a consensus price target of $1,012.56.

Plan Group Financial LLC bought a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 331 shares of the company's stock, valued at approximately $273,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LLY. WestEnd Advisors LLC lifted its position in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares in the last quarter. Citizens National Bank Trust Department boosted its position in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the first quarter valued at $40,000. Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company in the fourth quarter valued at about $43,000. Finally, O Brien Wealth Partners LLC increased its position in Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after purchasing an additional 12 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. UBS Group lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Leerink Partners downgraded shares of Eli Lilly and Company from an "outperform" rating to a "market perform" rating and set a $715.00 price target on the stock. in a report on Thursday. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Finally, Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. One analyst has rated the stock with a sell rating, four have issued a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $999.50.

Eli Lilly and Company Stock Down 14.2%

LLY traded down $106.20 on Thursday, hitting $640.17. 26,056,463 shares of the company were exchanged, compared to its average volume of 3,684,957. The company has a market cap of $606.71 billion, a PE ratio of 52.09, a PEG ratio of 1.06 and a beta of 0.44. Eli Lilly and Company has a 12 month low of $633.20 and a 12 month high of $972.53. The stock's fifty day moving average is $776.36 and its 200-day moving average is $799.60. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm's revenue for the quarter was up 37.6% on a year-over-year basis. During the same period in the previous year, the company earned $3.92 earnings per share. Equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.